These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 27264764

  • 21. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
    Fukao H, Yamamoto K, Matsuo O.
    Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Jul; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 25. Changes in the Fibrinolytic System of Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
    Abudouleh E, Alhamlan F, Al-Qahtani AA, Bohol MF, Al Hazzani A, Khorfan K, Alkaff M, Owaidah T, Al-Qahtani AA.
    J Clin Med; 2023 Aug 10; 12(16):. PubMed ID: 37629265
    [Abstract] [Full Text] [Related]

  • 26. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T.
    Am J Hematol; 2003 Jan 10; 72(1):1-7. PubMed ID: 12508260
    [Abstract] [Full Text] [Related]

  • 27. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 10; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 28. Effect of obesity on TAFI in postmenopausal period.
    Taskiran B, Guldiken S, Demir AM, Okman TK, Arikan E, Turgut B, Tugrul AA.
    Obes Res Clin Pract; 2010 Sep 10; 4(4):e247-342. PubMed ID: 24345692
    [Abstract] [Full Text] [Related]

  • 29. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
    Van Thiel DH, George M, Fareed J.
    Thromb Haemost; 2001 Apr 10; 85(4):667-70. PubMed ID: 11341503
    [Abstract] [Full Text] [Related]

  • 30. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
    Sakata Y, Murakami T, Noro A, Mori K, Matsuda M.
    Blood; 1991 May 01; 77(9):1949-57. PubMed ID: 1708294
    [Abstract] [Full Text] [Related]

  • 31. Fibrinolysis in disseminated intravascular coagulation.
    Hack CE.
    Semin Thromb Hemost; 2001 Dec 01; 27(6):633-8. PubMed ID: 11740686
    [Abstract] [Full Text] [Related]

  • 32. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
    Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T.
    Am J Hematol; 1991 Mar 01; 36(3):176-83. PubMed ID: 1899963
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.
    Vervloet MG, Thijs LG, Hack CE.
    Semin Thromb Hemost; 1998 Mar 01; 24(1):33-44. PubMed ID: 9515778
    [Abstract] [Full Text] [Related]

  • 35. Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
    Velasco F, Torres A, Rojas R, Alvarez MA, Gomez P, Castillo D.
    Haemostasis; 1992 Mar 01; 22(3):117-23. PubMed ID: 1427455
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 01; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 39. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B, Livnat T, Lubetsky A, Tamarin I, Budnik I, Einav Y, Martinowitz U.
    Blood Coagul Fibrinolysis; 2012 Jul 01; 23(5):370-8. PubMed ID: 22498982
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.